Background and aims: Radiopaque drug-eluting beads are an emerging treatment option for patients with hepatocellular carcinoma (HCC).The primary objective of this study was to evaluate overall disease and target tumor response of non-resectable HCC after TACE with a Router doxorubicin-loaded radiopaque microsphere.Methods: Data were abstracted from records of patients with unresectable HCC who received TACE with doxorubicin-loaded radiopaque LC Bead LUMITM microspheres at one of five United States centers between February 2016 - November 2017.
Response was measured using modified response criteria in solid tumors.Primary efficacy endpoints included objective response rate (ORR) and disease control rate (DCR) at first assessment post-treatment, both overall and for targeted tumors.ORR was the sum of complete and partial response.
DCR was ORR plus stable disease.Toxicity GLUCOSAMINE was calculated using common terminology criteria for adverse events.Results: Eighty-two patients were included.
Overall ORR and DCR were 47.6% (39/82) and 76.8% (63/82), respectively.
ORR and DCR of target tumors were 56% and 98%, respectively.Five patients experienced adverse events (5/82, 6.1%).
No grade 4-5 toxicities occurred.Conclusions: TACE with drug-loaded radiopaque beads is a promising treatment for unresectable HCC.Prospective studies should evaluate whether radiopaque beads reduce off-target distribution of microspheres.